Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$10.12
-$0.03(-0.47%)
At close: 4:00 PM EST
$10.12
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$4.55 - $11.85
Previous CloseN/A
Volume124.17K
Average Volume (3M)814.83K
Market Cap
$916.27M
Enterprise Value$846.99M
Total Cash (Recent Filing)$65.93M
Total Debt (Recent Filing)$88.69M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding81,446,130
10 Day Avg. Volume1,246,061
30 Day Avg. Volume814,826
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.41
Enterprise Value/Gross Profit11.06
Enterprise Value/Ebitda-10.09
Forecast
1Y Price Target
$21.00Price Target Upside107.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$128.65M
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceMulti-year phase 1 dose-escalation and follow-up data strengthen the gene therapy's efficacy and safety profile for radiation-induced dry mouth, increasing confidence in its potential benefit in later trials.
Funding And PartnershipsCash inflows and collaboration payments extend the development runway and reduce near-term financing risk, supporting continued program advancement and value realization through partnerships.
Ophthalmology Commercial PotentialPositive feedback from patients and physicians and completed technology transfer in the late-stage ophthalmology program enhance commercial readiness and support potential partner or milestone value.
Bears Say
Regulatory Timing UncertaintyUnclear scheduling of regulatory filings and pivotal trials creates uncertainty around when major value inflection points will occur, elevating investor visibility and execution risk.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings Plc’s price range in the past 12 months?
Meiragtx Holdings Plc lowest stock price was $4.55 and its highest was $11.85 in the past 12 months.
What is Meiragtx Holdings Plc’s market cap?
Meiragtx Holdings Plc’s market cap is $916.27M.
When is Meiragtx Holdings Plc’s upcoming earnings report date?
Meiragtx Holdings Plc’s upcoming earnings report date is May 07, 2026 which is in 17 days.
How were Meiragtx Holdings Plc’s earnings last quarter?
Meiragtx Holdings Plc released its earnings results on Mar 26, 2026. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.76.
Is Meiragtx Holdings Plc overvalued?
According to Wall Street analysts Meiragtx Holdings Plc’s price is currently Undervalued.
Does Meiragtx Holdings Plc pay dividends?
Meiragtx Holdings Plc does not currently pay dividends.
What is Meiragtx Holdings Plc’s EPS estimate?
Meiragtx Holdings Plc’s EPS estimate is -0.62.
How many shares outstanding does Meiragtx Holdings Plc have?
Meiragtx Holdings Plc has 81,446,130 shares outstanding.
What happened to Meiragtx Holdings Plc’s price movement after its last earnings report?
Meiragtx Holdings Plc reported an EPS of $0.19 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went down -1.181%.
Which hedge fund is a major shareholder of Meiragtx Holdings Plc?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (107.51% Upside)
$21.00 (107.51% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.5%
Last 30 Days ▲ 15.3%
Last 30 Days ▲ 15.3%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.06%
12-Months-Change
Fundamentals
Return on Equity
4438.87%
Trailing 12-Months
Asset Growth
-6.94%
Trailing 12-Months
Company Description
Meiragtx Holdings Plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$21.00
▲(107.51% Upside)
Technical Analysis
Ownership Overview
17.17% Insiders
2.21% Mutual Funds
0.11% Other Institutional Investors
77.02% Public Companies and
Individual Investors